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ABSTRACT 
Alopecia areata (AA) affects approximately 4.6 million individuals in the United 
States alone. It is typified by patchy hair loss on the scalp that can progress to cover the 
entire scalp (alopecia totalis), and eventually the entire body (alopecia universalis). 
Despite its high incidence, the genetic basis of AA is largely unknown. It is now 
generally accepted that AA fits the paradigm of a complex trait, in which a combination 
of genetic and environmental factors result in the final phenotype. Genetic studies have 
been limited thus far to association analyses, which suggest that a permissive HLA status 
may potentiate the development of AA. However, a systematic screen for identifying the 
primary genetic mechanisms underlying this disorder has never before been undertaken. 
Here, we discuss our approach towards the identification of susceptibility genes for AA. 
In particular, we have recently initiated a comprehensive genetic analysis of AA by 
performing a genome-wide scan in a collection of AA families with multiple affected 
family members. There are currently a number of examples of complex diseases of the 
skin, such as psoriasis and atopic dermatitis, in which genetic studies are being 
undertaken that substantiate the timeliness of this approach. We anticipate that these 
studies will lead to the identification of AA susceptibility genes, and provide a foundation 
for understanding the interactions of these genes with each other and with other variables 
such as the immune system and environmental factors. 
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INTRODUCTION 
 
Alopecia areata (AA) is typified by patchy hair loss on the scalp that can progress 
to cover the entire scalp (alopecia totalis, AT), and eventually the entire body (alopecia 
universalis, AU). AA affects approximately 4.6 million individuals in the U.S. alone, 
including males and females of all ages and ethnic groups (Price 1991; Sawaya and 
Hordinsky 1992; Schwartz and Janniger 1997; Madani and Shapiro 2000). Despite its 
high incidence, the pathomechanisms underlying AA are largely unknown. An 
autoimmune etiology has been suggested for many years, but an autoantigen has never 
been identified.  It is now generally accepted that AA fits the paradigm of a complex or 
multifactorial trait, in which genetic and environmental factors combine to result in the 
final phenotype (Green and Sinclair 2000; McElwee et al 2001; McDonagh and Tazi-
Ahnini 2002; McElwee and Hoffmann 2002). However, genetic studies have been 
restricted to association analyses, which suggest that a permissive HLA status may 
potentiate the development of AA. A systematic screen for identifying the primary 
genetic mechanisms underlying this disorder has never before been undertaken. 
Discovery of genes directly implicated in the pathogenesis of AA would have far-
reaching implications for basic science, and importantly, for affected individuals. The 
pathology of AA extends far beyond the physical aspects of hair loss, and can have a 
deeply disturbing psychological impact. The losses pertain not only to hair, but 
profoundly impact the quality of life, the ability to function in society and the 
preservation of self-esteem. There are few diseases as prevalent as AA in which a 
complete lack of understanding precludes prediction of disease course or even a widely 
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effective treatment. With the completion of the Human Genome Project, we are now 
well-positioned to begin a comprehensive genetic analysis of AA. Here, we describe our 
approach towards the identification of susceptibility genes for AA. We are performing a 
genome-wide scan in a large cohort of AA families with multiple affected family 
members. These studies will systematically pinpoint candidate susceptibility genes for 
AA, and potentially illuminate therapeutic targets for AA patients in the future. 
 
ALOPECIA AREATA: THE DISEASE 
It is estimated that AA affects between 2-4% of patients within average 
dermatology practices (Price 1991). It usually begins as one or several oval patches of 
nonscarring hair loss in the scalp. They can appear suddenly or more gradually over 
several days or weeks. The hair loss may regress, or on the contrary, the patches can 
coalesce and progress to cover the entire scalp (AT) and eventually the entire body (AU). 
AA is sometimes accompanied by nail changes in the form of pitting, brittleness and 
splitting. In all, the prognosis of AA is unpredictable and there is no definitive treatment. 
The pathogenetic basis and etiology of AA are largely unknown. In the initial 
stages, the number of hair follicles appears to remain the same, however, in the more 
advance stages, this number decreases and miniaturization of the anagen hair follicles is 
observed (McDonagh and Messenger 1996). A cardinal feature of AA is the presence of a 
lymphocytic infiltrate in the scalp biopsies of affected patients. This, together with the 
response of patients to steroid treatment, has led to the suggestion of an autoimmune 
mechanism for many years (Khoury et al 1988; Welsh et al 1994). Recently, it has been 
hypothesized that melanocyte-associated antigens could induce hair loss in AA (Gilhar et 
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al 2001). However, an autoantigen has never been identified. On the other hand, 
haplotype association studies suggest that a permissive HLA status may potentiate the 
development of the AA phenotype (Kianto et al 1977; Kuntz et al 1977; Hacham-Zadeh 
et al 1981; Morling et al 1991; Welsh et al 1994; Colombe et al 1995; de Andrade et al 
1999). While the studies describing a positive association between HLA and AA are 
numerous, there is a lack of biological data implicating specific alleles in the disease 
phenotype. Moreover, association between HLA and AA has been excluded in some 
familial cases of AA (Zlotogorski et al 1990). 
 
ALOPECIA AREATA: A COMPLEX TRAIT 
The term "complex trait" is used to describe any phenotype that does not exhibit 
classic Mendelian inheritance attributable to a single gene locus, but does have a genetic 
component as demonstrated by twin, adoption and epidemiological studies (Lander and 
Schork 1994). 
 
Polygenic Inheritance of Alopecia Areata 
No single resource of evidence for polygenic inheritance exists for AA, however, 
it is becoming increasingly evident that a significant genetic predisposition underlies the 
AA phenotype (Green and Sinclair 2000; McElwee et al 2001; McDonagh and Tazi-
Ahnini 2002; McElwee and Hoffmann 2002). There are several independent lines of 
evidence in favor of polygenic inheritance of AA (Aita and Christiano 2001). Among 
them, i) the high prevalence of the trait, typical of complex traits, for which the 
predisposing alleles are more common than the relatively rare mutations identified for 
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Mendelian disorders; ii) the Gaussian curve of distribution, for both the stages of disease 
progression and the distribution of AA, with a threshold effect that could be lowered by 
the presence of a particular HLA haplotype or autoimmune susceptibility, for example 
(Welsh et al 1994); iii) the heritability as defined by both the frequency of affected 
family members, ranging from 3 to 42% (Green and Sinclair 2000), and concordance in 
twins (Jackow et al 1998); and finally, iv) the presence of congenital AA, strongly 
suggesting the contribution of genetic factors (de Viragh et al 1997; Bardazzi et al 1999; 
Bereket et al 2001; Crowder et al 2002). In addition, Sundberg and coworkers (J.P.S., in 
this issue) have reported the identification of potential susceptibility loci underlying the 
AA phenotype in the C3H/HeJ mouse model for AA. 
 
Association Studies in AA 
As a first attempt to identify the genetic basis of AA, a number of association studies for 
candidate genes have been conducted. There are numerous reports that indicate a 
significant association between AA and the HLA alleles DQB1*0301 (for severe AA) 
and DRB1*1104 (Morling et al 1991; Welsh et al 1994). In a family-based study, 
DQB1*03 alleles were shown to be present in 85% of AA patients as compared to 46% of 
controls (de Andrade et al 1999). Several authors have also suggested association with 
the IL-1 receptor antagonist gene (IL1RN) and IL-1 receptor antagonist homologue IL-
1L1 (Tarlow et al 1994; Barahamani et al 2002; Tazi-Ahnini et al 2002), as well as with 
the MX1 gene on chromosome 21 (Tazi-Ahnini et al 2000). Finally, strong association 
between autoimmune polyglandular syndrome type 1 (APS1), caused by mutations in the 
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AIRE gene on chromosome 21, and AA has also been reported (Betterle et al 1998). In 
their study, Betterle et al (1998) observed AA in 37% of their APS1 patients. 
 
Linkage Analysis in Complex Traits 
Genome-wide scan on large cohorts of patients is currently the strategy more 
frequently applied with success for the study of complex traits. As an example, a number 
of groups have performed genome-wide scans in affected families with psoriasis, and 
have identified at least three predisposing genetic loci on chromosomes 4, 6 and 17 
(Bhalerao and Bowcock 1998). Atopic dermatitis, another complex skin disease, has also 
been the subject of genetic studies (Lee et al 2000; Söderhäll et al 2001; Bradley et al 
2002). Lee et al (2000) have reported the identification of a major susceptibility locus on 
chromosome 3. It is anticipated that this type of study will lead to the identification of the 
pathomechanisms for these common diseases, as has been the case for Crohn's disease, 
with the identification of the actual alleles conferring susceptibility in the NOD2 gene 
(Hugot et al 2001; Ogura et al 2001). 
 
IDENTIFYING SUSCEPTIBILITY GENES FOR ALOPECIA AREATA 
Genome-wide Scan 
 As discussed above, the genome-wide linkage strategy has been widely applied for 
the study of complex traits. The design of a complex trait study is dependent on a few 
variables: i) the collection of families; ii) the number and spacing of genetic markers; and 
iii) the statistical power to identify a locus as a function of these choices. These three 
considerations of the study design are addressed in the following sections. 
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I. Diagnostic Criteria and Ascertainment of Alopecia Areata Families 
 Critical to the success of any genome-wide initiative for a complex disease, a 
patient collection initiative must fulfill a number of requirements: i) accurate and uniform 
diagnosis; ii) a large size for the results to be significant; iii) a sample in which the 
contribution of genetic factors is enriched; and iv) a sample amenable to be analyzed as a 
single group, or as smaller, more homogeneous subgroups. 
 Although AA presents with some cardinal morphological and histological features, 
its diagnosis can be complicated by the variability in the hair loss and characteristic 
waxing and waning nature of the disease. To achieve homogeneity in the collection of 
families, the ascertainment, diagnosis and collection of the families included in our study 
is being undertaken by dermatologists with longstanding expertise in AA and using the 
diagnostic questionnaire developed by the NIH AA Registry. The sources of the AA 
families recruited for this study comprise a large group of families from the Israeli 
Registry ascertained and diagnosed personally by A. Z., as well as families from the NIH 
AA Registry and different physicians in the U.S. 
 An example of the patient collection used in our study is shown in Figure 1 and 
summarized in Table I, showing a family history in 35% of the patients examined. The 
genetic dissection of complex traits has traditionally been focused in large collections of 
small families (affected sib pairs, for example). However, it has recently been shown that 
a small sample of larger pedigrees can potentially derive better results (Tomfohrde et al 
1994; Hugot et al 1996; Matthews et al 1996). The rationale for this is the following: 
first, the use of a small sample reduces the level of genetic heterogeneity ("noise") among 
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the pedigrees, one of the hallmarks of complex traits; second, a major contribution of 
genetic factors is suspected in those pedigrees with several affected family members (i.e., 
such families are "enriched" for predisposing alleles). Finally, knowing the relationship 
between the individuals in a large pedigree results in higher statistical power (Terwilliger 
and Goring 2000). In order to maximize the success of the gene-mapping study for AA, 
we have focused our initial efforts of the genome-wide scan in pedigrees with three or 
more affected family members. Importantly, such a collection of families is amenable to 
the establishment of different subsets, based on severity of the disease (patchy AA, AT or 
AU) or ethnic origin, among other criteria. 
 
II. Genetic Markers 
In order to achieve statistically significant results, a sufficient number of highly 
polymorphic markers must be genotyped. There are some reports on successful results 
with a low number of markers, such as the identification of the PSOR1 and IBD1 loci, 
conferring susceptibility to psoriasis and Crohn's disease, respectively (Matthews et al 
1996; Trembath et al 1997; Hugot et al 2001). In our study, however, we have chosen to 
perform a genome-wide scan using a panel of 324 microsatellite markers, with an average 
marker spacing of 10 cM and a semi-automated fluorescence-based genotyping system. 
Most of the markers are chosen from version 8.0 of the Marshfield fluorescence-labeled 
genome screening set. This approach has been described in detail elsewhere (Aita et al 
1999; Liu et al 2001; Liu et al 2002) and utilized by our group in collaboration with the 
Columbia University Genome Center (Ahmad et al 1998a; Ahmad et al 1998b; Martinez-
Mir et al 2002). 
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III. Statistical Analysis 
 Due to the inherent nature of complex traits, it is expected that a number of genetic 
components will be contributing to the final presentation of the phenotype. However, 
different combinations of genetic factors can be contributing to the disease in each 
family. For this reason, once the data-set from the genome-wide scan is obtained, it is 
extremely critical to perform a thorough and exhaustive statistical analysis to extract all 
possible information. These data-sets are amenable to be analyzed with a large number 
and wide variety of statistical tests. 
 As a first approach, we will apply the following test statistics to the data-set 
obtained in the genome-wide scan: i) the heterogeneity LOD score (Smith 1963; Ott 
1999), maximized over four settings of the penetrance parameters (MAXHLOD); and ii) 
the mean test for affected sib-pairs, as implemented in the ANALYZE program 
(Terwilliger and Ott 1994) (ASP); a test of allele sharing that uses all sibs (Terwilliger 
and Ott 1994) (ALLSIBS); and a likelihood version of the transmission disequilibrium 
test (Spielman et al 1993), as developed by Terwilliger (Terwilliger 1995) (TDT-LIKE). 
 With the MAXHLOD calculations, we apply a model-based linkage analysis in 
which the LOD score is calculated under both autosomal dominant and autosomal 
recessive patterns of inheritance. For both models, two different values of penetrance are 
considered, 50 and 80%. ASP, ALLSIBS and TDT-LIKE tests, on the other hand, are 
chosen because they all are genetic model-free tests (Elston 1989; Hodge and Elston 
1994), in the sense that they do not require a specification of the genetic model 
parameters (penetrance and disease allele frequency). MAXHLOD is used because it has 
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been shown that it is at least as powerful in localizing disease loci as tests like ASP and 
ALLSIBS (Abreu et al 1999), and is, under certain circumstances, a more precise 
indicator of the location of a disease locus than statistics like ASP and ALLSIBS (Finch 
et al 2001). Finally, TDT-LIKE is chosen because it has been shown that it may be more 
powerful than linkage tests (MAXHLOD, ASP, ALLSIBS) when there is linkage and 
linkage disequilibrium between a disease and a marker locus. Some of the AA families 
collected by A.Z. in Israel are Ashkenazi Jewish (AJ). The AJ population is considered a 
genetically isolated population and the extent of linkage disequilibrium is thought to 
extend over larger regions of the human genome (Ostrer 2001).  The strategy used here is 
similar to exploratory methods employed by other researchers analyzing genome-scan 
data for complex traits (Wise et al 1999; Wise and Lewis 1999), with the exception that 
we will study a whole chromosome at a time, rather than subdividing each chromosome 
into bins. We consider the whole chromosome as the unit of measure because in 
simulated data-sets it has been observed that the methods we plan to employ are more 
powerful at determining the correct chromosome, rather than a particular region of a 
chromosome harboring a disease susceptibility locus (Gordon et al 2001). 
 
Identification of Genes and DNA Variants Conferring Genetic Susceptibility for 
Alopecia Areata 
 Once a complex trait has been mapped to one or several susceptibility loci, the task 
of identifying the specific alleles conferring susceptibility for the phenotype of interest 
still remains. First, a small interval of amenable size for positional cloning is rarely 
identified in initial linkage studies. Second, the nature of a complex disease implies that 
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the alleles predisposing to the final phenotype can be numerous. Finally, common 
polymorphisms, rather than nonsense or frameshift mutations, are the expected gene 
variants contributing to the etiology of complex traits. For this reason, multiple 
approaches are utilized towards the identification of candidate susceptibility genes and 
alleles for AA. 
 
I. Fine-Mapping of Susceptibility Loci for Alopecia Areata 
 The results from the first stage of the genome-wide scan, as described above, are 
expected to indicate the most likely location for the susceptibility genes for AA. In order 
to confirm the results from this first stage, as well as to exclude false positive results, a 
second stage of analysis is performed. A dense map of polymorphic markers in the 
regions of interest is developed using both microsatellite markers and SNPs. These are 
available in the public databases, such as UCSC, NCBI, Ensembl, and deCODE Genetics 
(Kong et al 2002), for map and sequence information on microsatellites and SNPs; the 
Marshfield genetic map (Broman et al 1998), for map information on microsatellites; and 
the SNP consortium database (Sachidanandam et al 2001), for SNP selection. The entire 
collection of AA families, together with newly collected pedigrees, can then be 
genotyped in this fine-mapping stage. In the case SNP analysis is required for a large 
genomic region, and in order to optimize the genotyping effort in this refinement stage, 
the presence of haplotype blocks can be determined (Daly et al 2001; Gabriel et al 2002). 
The use of haplotype blocks can considerably reduce the cost of genotyping, since a few 
SNPs are typed which represent the entire haplotype. Similar statistical analyses as those 
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described above can be applied to exclude those regions in the genome that could 
represent false positives and to map the actual susceptibility loci for AA. 
 
II. Identification of Candidate Genes 
 Once the candidate regions cannot be further refined, it is necessary to proceed with 
the analysis of the genes therein by both in silico and experimental procedures. We now 
have access to continuous updated sequence data of the human genome at three main 
databases, UCSC, NCBI and Ensembl. Based on the information available from these 
databases, a detailed physical map of the region of interest is built in order to prioritize 
the candidate genes to be analyzed. This usually includes previously known genes, novel 
genes, ESTs and predicted genes.  As a second but parallel approach in the case of AA, 
we can cross-reference the positional data from the genome-wide scan with expression 
data. In particular, Carroll et al (2002) have already performed expression studies in 
human AA patients and in a mouse model for AA. As a result, they have established 
between two groups of differentially expressed genes for the initial and late stages of 
disease development.  Finally, several animal models for AA have been described. 
Among them, the C3H/HeJ mouse and the DEBR rat have been extensively characterized 
(McElwee and Hoffmann 2002). Recently, Sundberg and coworkers (J.P.S., in this issue) 
have reported the first attempt for the identification of genes underlying the AA 
phenotype in the C3H/HeJ mouse model. As a result, several suggestive loci have been 
identified on chromosomes 9 and 17. The study of the syntenic regions containing AA 
loci in mouse and human can help in defining candidate genes. 
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III. Gene Characterization and Detection of DNA Variants 
 Once a candidate gene has been identified the final goal is the characterization of 
the actual alleles conferring susceptibility to the phenotype of interest. With this aim, the 
candidate gene is sequenced in a collection of patients and control individuals. 
 Since genomic DNA is the material used in a genome-wide scan, it is necessary to 
know the genomic structure of the candidate gene for PCR primer design. The strategy 
followed will depend on the available information on each gene. For those genes fully 
sequenced as part of the Human Genome Project public efforts, the intron/exon 
boundaries are known or can otherwise be determined by cDNA and genomic sequence 
comparison. For those genes partially sequenced, a PCR-based cloning strategy can be 
followed. Finally, in the case of predicted genes, the predicted gene structure must be 
verified by RT-PCR. 
 For each candidate gene, intron/exon boundaries will eventually be identified, as 
well as flanking intron sequences for the design of exon-specific PCR amplification 
primers for the detection of DNA variants. For each gene both coding and non-coding 
regions, mainly the promoter region, can then be analyzed. The first samples to be 
sequenced will be usually those corresponding to the pedigrees linked to a particular 
chromosomal region. Once DNA variants are identified, both in coding and non-coding 
sequences, it is necessary to test whether they are significantly associated to the disease 
phenotype. With this goal, their frequency can be determined in the complete collection 
of AA families, isolated AA cases and a control-matched population. If needed, the 
cohort of AA pedigrees can be further subdivided according to severity and ethnic origin 
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to test for associations between the variants identified and particular subgroups of the 
patient collection. 
We anticipate that this type of studies will provide a foundation for understanding 
the interactions of these genes with each other and with other variables such as the 
immune system and environmental triggers. Ultimately, it is expected that they will help 
to define therapeutic targets for the future, and eventually provide an effective treatment 
for this psychologically devastating dermatologic disorder. 
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Figure 1. Representative example of AA pedigrees available for this study. 
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Table I. Summary of AA patients examined 
 
Number of 
affected family members 
Number of 
cases 
1 (no family history) 91 
2 28 
3 10 
4 5 
5 3 
6 1 
7 1 
8 1 
 
 
 
